Psoriatic Arthritis Working Group

About

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease occurring in 7–42% of patients with psoriasis. Arthritis, enthesitis, dactylitis, spondylitis, and skin disease result in pain, stiffness, reduced mobility, impairment in physical function, and subsequent disability. PsA is now recognized as a disease that can be serious and progressive despite treatment, resulting in significant physical, psychological, functional, and social impairment.

The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.

Current Stage in the OMERACT Process

The group continues work on endorsing instruments across multiple domains and composite outcomes. Ongoing systematic reviews will inform final recommendations for use in trials.

Latest Update

Current Objectives and Focus Areas
4 domains that were prioritized:
  1. Enthesitis and dactylitis: Systematic literature review for clinical enthesitis/ dactylitis ongoing. US enthesitis, systematic review completed. No suitable instrument. Development of new instrument ongoing.
  2. Fatigue: Systematic literature review ongoing
  3. Physical Function: Provisionally endorsed HAQ-DI and SF36-PF. Completed comparing RCT discrimination between PF PROMs.
  4. Radiographic damage: systematic literature review and Delphi for domain match/feasibility completed. No instrument has adequate data for endorsement.
The working group has initiated the work for composite outcome measures. Completed systematic literature review on 6 composite outcome measures. Gathering data for endorsement of 3 composite outcome measures.
Composites Roadmap (1)

Meet the Team

Dafna Gladman

Dafna Gladman, Canada
Chair

Katy Leung

Katy Leung, Singapore
Chair

Ana-Maria Orbai

Ana-Maria Orbai, USA
Chair

William Tillett

William Tillett, UK
Chair

Niti Goel

Niti Goel, USA
Patient Research Partner

OMERACT Core Domain Set for Psoriatic Arthritis

PsA OMERACTEndorsed-Onionsfor-joint-health-conditions-1-1

Untitled design (2)

OMERACT Instrument Selection Endorsements

Recent Publications

  1. Antony, Anna, et al. “Measurement Properties of Radiographic Outcome Measures in Psoriatic Arthritis: A Systematic Review from the GRAPPA-OMERACT Initiative.” Seminars in Arthritis and Rheumatism, vol. 51, no. 2, 2021, pp. 367–86, https://doi.org/10.1016/j.semarthrit.2021.01.008.

  2. Leung, Ying-Ying, et al. “OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF.” Seminars in Arthritis and Rheumatism, vol. 51, no. 5, 2021, pp. 1117–24, https://doi.org/10.1016/j.semarthrit.2021.07.014.

  3. Duarte-García, Alí, et al. “Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.” Journal of Rheumatology, vol. 46, no. 8, 2019, pp. 996–1005, https://doi.org/10.3899/jrheum.181089.

  4. Orbai, Ana-Maria, et al. “PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-Specific Health-Related Quality of Life in Clinical Trials.” Journal of Rheumatology, vol. 46, no. 8, 2019, pp. 990–95, https://doi.org/10.3899/jrheum.181077.

  5. Orbai, Ana-Maria, et al. “Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.” Journal of Rheumatology, vol. 44, no. 10, 2017, pp. 1522–28, https://doi.org/10.3899/jrheum.160904.

New to OMERACT?

OMERACT Working Groups follow a structured, consensus-driven approach to developing Core Outcome Sets. Explore how this process unfolds and discover more about how OMERACT advances outcome measurement in rheumatology.

Learn More

Scroll to Top